Keyhole limpet hemocyanin clinical trials
How each study uses keyhole limpet hemocyanin is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
12 studies that test it; most in 2011 (2)
| Year | Studies |
|---|---|
| 1995 | 1 |
| 1998 | 1 |
| 2000 | 1 |
| 2001 | 1 |
| 2003 | 1 |
| 2007 | 1 |
| 2008 | 1 |
| 2011 | 2 |
| 2012 | 1 |
| 2019 | 1 |
| 2023 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 3 · Other 9
National Cancer Institute (NCI) (2) · National Institute of Allergy and Infectious Diseases (NIAID) (2) · Ono Pharmaceutical Co. Ltd (1) · Celldex Therapeutics (1) · Intracel (1) · Medical University of Graz (1) · University of Nebraska (1) · Masonic Cancer Center, University of Minnesota (1)
Often tested with
Tested in the same studies.
Sargramostim (2) · Besufetamig (1) · Rindopepimut (1) · Interleukin-4 (1) · Endotoxins (1) · Autologous Tumor Cell Vaccine (1) · Tetanus Toxoid (1) · Granulocyte-Macrophage Colony-Stimulating Factor (1)
Studies
Open first, then newest update. How each study uses keyhole limpet hemocyanin is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 12
- Single Ascending Dose Study to Assess the Safety, Tolerability, PK and PD of ONO-4685 in Japanese and Caucasian Healthy Adult Male SubjectsCompletedPhase 1Ono Pharmaceutical Co. LtdNCT04079062Written as KLHHow we know
- Vaccine Therapy in Treating Patients With Multiple MyelomaCompletedPhase 2National Cancer Institute (NCI)NCT00019097Written as keyhole limpet hemocyaninHow we know
- Vaccine Therapy Following Chemotherapy & Peripheral Stem Cell Transplantation in Treating Non-Hodgkin's LymphomaTerminatedPhase 2University of NebraskaNCT00006478Written as keyhole limpet hemocyaninHow we know
- KLH Challenge to Explore the Human Immune ResponseStatus unknownNot applicableUniversity of OxfordNCT05876195Written as Keyhole-Limpet HemocyaninHow we know
- A Study of Rindopepimut/GM-CSF in Patients With Relapsed EGFRvIII-Positive GlioblastomaCompletedPhase 2Celldex TherapeuticsNCT01498328Written as KLHHow we know
- CpG 7909 in Treating Patients Who Have Undergone Autologous Stem Cell TransplantTerminatedPhase 1Masonic Cancer Center, University of MinnesotaNCT00369291Written as keyhole limpet hemocyaninHow we know
- Wilm's Tumor 1 Protein Vaccine to Treat Cancers of the BloodCompletedPhase 1/2National Cancer Institute (NCI)NCT00923910Written as KLHHow we know
- Responses to Immunization With Keyhole Limpet Hemocyanin Administered by Scarification and the Intradermal RouteCompletedPhase 1National Institute of Allergy and Infectious Diseases (NIAID)NCT00614731Written as KLH carrier-proteinHow we know
- A Study to Determine the Immunogenicity and Oral Tolerance to Keyhole Limpet Hemocyanin (KLH)TerminatedEarly Phase 1National Institute of Allergy and Infectious Diseases (NIAID)NCT01489956Written as Immucothel Alone (Part A)How we know
- S0114 Vaccine Therapy in Treating Patients With Gastric, Prostate, or Ovarian CancerTerminatedPhase 1SWOG Cancer Research NetworkNCT00023634Written as KLHHow we know
- Keyhole Limpet Hemocyanin Compared With Doxorubicin in Treating Patients With Bladder CancerCompletedPhase 3IntracelNCT00006034Written as keyhole limpet hemocyaninHow we know
- Keyhole Limpet Hemocyanin in Chronic Hepatitis CCompletedNot applicableMedical University of GrazNCT01509391Written as keyhole-limpet hemocyaninHow we know
Given beside what is tested · 10 — keyhole limpet hemocyanin is usual care or a partner of the new treatment
- A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of TNX-1500 in Healthy SubjectsCompletedPhase 1Tonix Pharmaceuticals, Inc.NCT07473752Written as Keyhole Limpet Hemocyanin (KLH)How we know
- Study of Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Intravenous and Subcutaneous Single and Repeated Doses of SAR441344 in Healthy Adult SubjectsCompletedPhase 1SanofiNCT05845996Written as Keyhole limpet hemocyaninHow we know
- A Study to Evaluate the Effects of Ocrelizumab on Immune Responses In Participants With Relapsing Forms of Multiple SclerosisCompletedPhase 3Hoffmann-La RocheNCT02545868Written as KLHHow we know
- A Toll-like Receptor Agonist as an Adjuvant to Tumor Associated Antigens (TAA) Mixed With Montanide ISA-51 VG With Bevacizumab for Patients With Recurrent GlioblastomaWithdrawnPhase 2NYU Langone HealthNCT02754362Written as Keyhole limpet hemocyanin (KLH)How we know
- Study to Assess Safety, Tolerability and Immune Response of Fimaporfin-induced Photochemical Internalisation of Antigen/AdjuvantCompletedPhase 1PCI Biotech ASNCT02947854Written as KLH (Keyhole Limpet Hemocyanin)How we know
- A Study to Evaluate the Effects of Rituximab on Immune Responses in Subjects With Active Rheumatoid Arthritis Receiving Background MethotrexateCompletedPhase 2Genentech, Inc.NCT00282308Written as Keyhole limpet hemocyaninHow we know
- The Effects of Tysabri Treatment on Vaccination Response and Lymphocyte Subsets in Subjects With Relapsing Forms of Multiple SclerosisCompletedPhase 4BiogenNCT00536120Written as keyhole limpet hemocyanin (KLH)How we know
- Study to Evaluate the Safety, Tolerability, PK, and PD of BMS-986090 in Healthy SubjectsTerminatedPhase 1Bristol-Myers SquibbNCT02079480Written as Keyhole limpet hemocyaninHow we know
- A Study to Assess Immune Response in Pediatric Kidney Transplant Recipients Treated With Daclizumab (Zenapax)CompletedPhase 4Hoffmann-La RocheNCT02576145Written as KLHHow we know
- Vaccine Therapy Plus QS21 in Treating Patients With Progressive Prostate CancerCompletedPhase 1Memorial Sloan Kettering Cancer CenterNCT00003819Written as keyhole limpet hemocyaninHow we know
As the comparator · 1 — what is tested is compared with keyhole limpet hemocyanin
Codes
What other systems call keyhole limpet hemocyanin · ClinicalTrials.gg INT002990
- MeSH (NLM) C032808keyhole-limpet hemocyaninConfirmed ClinicalTrials.gov, NLM
- UNII (FDA) FV4Y0JO2CXKEYHOLE LIMPET HEMOCYANINConfirmed FDA, NLM
- NCI Thesaurus C1139Keyhole Limpet HemocyaninOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C032808 | keyhole-limpet hemocyanin | Confirmed ClinicalTrials.gov, NLM |
| UNII (FDA) | FV4Y0JO2CX | KEYHOLE LIMPET HEMOCYANIN | Confirmed FDA, NLM |
| NCI Thesaurus | C1139 | Keyhole Limpet Hemocyanin | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.